Skip to main content
LYSOGENE logo

LYSOGENE — Investor Relations & Filings

Ticker · LYS ISIN · FR0013233475 LEI · 969500T64RILK1RD0852 PA Professional, scientific and technical activities
Open in API
Filings indexed 254 across all filing types
Latest filing 2018-04-16 Earnings Release
Country FR France
Listing PA LYS

About LYSOGENE

https://www.lysogene.com

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Recent filings

Filing Released Lang Actions
Quarterly financial report / First quarter financial report
Earnings Release Classification · 1% confidence The document is explicitly titled "Lysogene Reports First Quarter Financial Results and Provides Business Update" and is dated April 16, 2018. It details the cash position as of March 31, 2018, and provides updates on clinical trials and management appointments. This structure—reporting on a specific, shorter fiscal period (First Quarter) with key financial highlights and operational updates—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or a detailed Interim/Quarterly Report (IR), as it focuses on highlights and cash position rather than full financial statements, although it contains some financial data. It is a press release announcing results, fitting the ER definition best. Q1 2018
2018-04-16 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated February 6, 2018, announcing that Lysogene received a positive opinion from the European Medicines Agency (EMA) regarding its Paediatric Investigation Plan (PIP) for a gene therapy candidate (LYS-SAF302). This announcement relates to regulatory progress and clinical trial planning for a specific drug. It is not a full Annual Report (10-K), an Earnings Release (ER), a Call Transcript (CT), or a formal Audit Report (AR). It is an announcement concerning regulatory/clinical progress, which often falls under general Regulatory Filings (RNS) or, if it were a presentation, an Investor Presentation (IP). Since it is a press release detailing a specific regulatory milestone (EMA PIP approval) that paves the way for a Clinical Trial Application (CTA) and future Marketing Authorization Application (MAA), it is best classified as a general Regulatory Filing (RNS) or potentially a Legal/Regulatory Update (LTR) if the focus was on litigation, but RNS is the most appropriate general category for miscellaneous regulatory news that doesn't fit the other specific codes like DIV, DIRS, or MANG. Given the options, RNS serves as the best fit for this type of specific, non-financial, non-governance regulatory news update.
2018-02-06 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated February 6, 2018, announcing that Lysogene received a positive opinion from the European Medicines Agency (EMA) regarding its Pediatric Investigation Plan (PIP) for LYS-SAF302. This announcement relates to regulatory progress and clinical trial planning for a drug candidate. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Call Transcript (CT). Since it details a specific regulatory milestone (EMA PIP validation) that is crucial for future marketing authorization, it falls under the category of general regulatory or corporate information. Given the options, this type of announcement, which is a formal communication about regulatory progress rather than a financial report or a specific insider transaction, is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if it heavily implied fundraising, but here the focus is purely regulatory/clinical progress. Since RNS is the general regulatory announcement fallback and this is a press release detailing a regulatory step, RNS is the most appropriate fit among the provided codes, as it is not a specific financial report or management change announcement.
2018-02-06 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release dated February 1, 2018, announcing that the company, Lysogene, will present 5-year clinical data on MPS IIIA at the 14th annual WORLDSymposium™. It details the presentation title, speaker (Dr. Sophie Olivier), date (February 8th), and location. It also mentions a poster presentation. This type of announcement, detailing participation in an external scientific conference to present research findings, is best classified as an Investor Presentation (IP) or a general announcement. Since it is an announcement about presenting data at a scientific forum, which is highly relevant to investors, 'Investor Presentation' (IP) is a strong fit, as it often covers research updates. However, given the context of a press release announcing participation in a scientific meeting, and the fact that it is not a formal company presentation deck, it could also be seen as a general regulatory announcement. Comparing the options, 'IP' (Investor Presentation) covers detailed presentations of strategy and financials, which scientific data supports. If the document were just a short notice saying 'we will be at the conference,' 'RPA' or 'RNS' would be better. Since it provides specific details about the data being presented (5-year clinical data, study plan), it leans towards providing substantive investor information. Given the options, 'IP' is the most specific category for presenting detailed research/clinical updates to investors, even if announced via a press release. If 'IP' is too broad, 'RNS' (Regulatory Filings/General Announcement) is the fallback. I will classify it as 'IP' because the core content is the presentation of clinical data, which is a key component of investor relations material.
2018-02-01 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release dated February 1st, 2018, announcing that Lysogene will be presenting clinical data at the 14th Annual WORLD*Symposium*™. It details the presentation title, presenter, date, and location of the scientific conference presentation. This content is not a formal regulatory filing (like 10-K, IR, or ER), nor is it a general investor presentation (IP) or a management discussion (MDA). It specifically relates to materials being shared at an Annual General Meeting or a similar major industry event where company data is presented. Since the definition for AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)', and this document announces participation and presentation of clinical data at a major industry symposium, it aligns best with the spirit of sharing key company/clinical updates intended for investors and stakeholders, similar to AGM materials, although it is not strictly an AGM. However, given the options, this is an announcement about presenting clinical data at a major event. If the document itself were the presentation slides, it would be IP. Since it is an announcement about presenting at a scientific meeting, and there is no specific code for 'Scientific Conference Presentation Announcement', I must choose the closest fit. It is an announcement of company activity and data presentation. Given the context of financial reporting categories, this type of announcement often accompanies or precedes investor updates. Since it is an announcement about presenting data, and not the data itself, and it is not a standard regulatory filing, I will check the definitions again. It is not a Call Transcript (CT), Earnings Release (ER), or Interim Report (IR). It is an announcement of company activity. The closest fit among the provided options that captures the nature of sharing key company/clinical updates intended for stakeholders, often associated with shareholder events, is AGM-R, although it is a scientific symposium. If the document were a presentation deck, it would be IP. As a press release announcing participation in a major industry event where data is shared, it is closest to an AGM-R announcement, or potentially RNS if it were purely regulatory. Given the focus on clinical data presentation, and lacking a better fit, I will classify it as related to shareholder/investor updates, leaning towards AGM-R as the most relevant event-based disclosure type, or RNS as a general announcement. Given the content is highly specific to clinical data presentation at a symposium, and not a formal regulatory filing, RNS is a safer fallback if AGM-R is too specific to the AGM itself. However, since it is a formal announcement of company progress intended for investors, and often these symposia are key investor events, AGM-R is plausible. I will select RNS as the most appropriate general regulatory announcement/press release category when a specific event type (like a scientific symposium announcement) is missing, as it is a general announcement about company activity.
2018-02-01 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release dated January 3, 2018, titled "BILAN ANNUEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT" (Annual Balance of the Liquidity Contract with Stock Brokerage Firm Gilbert Dupont). It details the status of a liquidity contract (share count and cash balance) as of December 29, 2017, comparing it to the previous semi-annual balance from June 30, 2017. This type of announcement, which reports on specific financial arrangements or operational activities outside of standard periodic financial reports (like 10-K or IR), fits best under the general category for regulatory announcements or specific operational updates. Since it is not a standard financial report (ER, IR, 10-K), a dividend notice (DIV), or a management change (MANG), and it relates to the company's financial structure/market operations, it is most appropriately classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the liquidity contract is viewed as a financing tool. Given the context of reporting on a specific, non-standard financial agreement (liquidity contract balance), RNS serves as the most appropriate general regulatory disclosure category when a more specific code is unavailable. It is not a presentation (IP) or a formal audit report (AR).
2018-01-03 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.